Kodiak Sciences Inc.
KOD · Nasdaq · United States
Share price · KOD
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when KOD's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 28 Sep 2026+178.0%
- 26 Mar 2026+74.8%
- 30 Jan 2026-10.5%
Nothing announced by KOD that day or the session before.
Share of unusual movement by asset
For each asset, the share of KOD's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | VEGF + IL-6Multispecific antibody | Indication not yet linked | |
| Phase 3 | VEGF + IL-6Multispecific antibody | Age-Related Macular DegenerationDiabetic Macular Edema | |
| Phase 3 | VEGF-AMonoclonal antibody | Age-Related Macular Degeneration Wet Age-Related Macular Degeneration |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (17)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $58M | $89M | $66M-$44M operating cash flow | report ↗ |
View 16 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $56M | $126M | $66M-$46M operating cash flow | report ↗ |
| 2026-Q1 | — | $49M | $170M | $58M-$40M operating cash flow | report ↗ |
| 2025-Q3 | — | $50M | $72M | $61M-$33M operating cash flow | report ↗ |
| 2025-Q2 | — | $43M | $104M | $54M-$35M operating cash flow | report ↗ |
| 2025-Q1 | — | $44M | $139M | $57M-$29M operating cash flow | report ↗ |
| 2024-Q3 | — | $32M | $198M | $44M-$21M operating cash flow | report ↗ |
| 2024-Q2 | — | $33M | $219M | $45M-$26M operating cash flow | report ↗ |
| 2024-Q1 | — | $30M | $246M | $43M-$40M operating cash flow | report ↗ |
| 2023-Q3 | — | $36M | $346M+ $0 short-term inv. | $50M-$33M operating cash flow | report ↗ |
| 2023-Q2 | — | $67M | $379M+ $0 short-term inv. | $80M-$42M operating cash flow | report ↗ |
| 2023-Q1 | — | $57M | $317M+ $105M short-term inv. | $71M-$47M operating cash flow | report ↗ |
| 2022-Q3 | — | $62M | $178M+ $359M short-term inv. | $77M-$53M operating cash flow | report ↗ |
| 2022-Q2 | — | $74M | $173M+ $425M short-term inv. | $91M-$55M operating cash flow | report ↗ |
| 2022-Q1 | — | $76M | $672M | $96M-$43M operating cash flow | report ↗ |
| 2021-Q4 | — | — | $732M+ $0 short-term inv. | $93M-$59M operating cash flow | report ↗ |
| 2021-Q3 | — | $56M | $799M | $68M-$52M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $182M | $210M | $57M-$136M operating cash flow | report ↗ |
Kodiak Sciences did not disclose revenue for 2025. R&D expenses were $182.37M, up 44.6% YoY, and the company ended the year with $209.86M in cash and cash equivalents. The full-year net loss was $229.97M.
The company reported positive Phase 3 topline results from GLOW2, showing Zenkuda (tarcocimab tedromer) was superior to sham in diabetic retinopathy, and said it plans to accelerate toward a multi-indication Biologics License Application submission. Enrollment has completed in the Phase 3 DAYBREAK study of Zenkuda and KSI-501 in wet AMD, with topline data expected in September 2026; topline results for the KSI-101 Phase 3 PEAK and PINNACLE studies are expected in 4Q 2026 and 2Q 2027, respectively. In December 2025, Kodiak completed an equity offering with net proceeds of $173.0M, and management stated that current cash supports planned operations into 2027.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $126M | $168M | $44M-$117M operating cash flow | report ↗ |
| 2023-FY | — | $206M | $286M+ $0 short-term inv. | $65M-$154M operating cash flow | report ↗ |
| 2022-FY | — | $268M | $190M+ $289M short-term inv. | $83M-$206M operating cash flow | report ↗ |
| 2021-FY | — | $217M | $732M+ $0 short-term inv. | $67M-$182M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 88 purchases ($241.3M), 14 sales ($4.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-05 | BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN · director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner | Open-market purchase | 4,703 | $98.51 | $463K | Form 4 |
| 2026-11-05 | BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN · director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner | Open-market purchase | 81,729 | $98.51 | $8.1M | Form 4 |
| 2026-11-04 | BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN · director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner | Open-market purchase | 8,742 | $98.51 | $861K | Form 4 |
| 2026-11-04 | BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN · director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner | Open-market purchase | 151,916 | $98.51 | $15.0M | Form 4 |
| 2026-10-23 | Yang Taiyin · director | Option exercise | 20,000 | $2.35 | $47K | Form 4 |
| 2026-10-23 | Yang Taiyin · director | Option exercise (derivative) | 20,000 | — | — | Form 4 |
| 2026-10-21 | BORGESON JOHN A. · Chief Financial Officer | Option exercise | 30,000 | $2.49 | $75K | Form 4 |
| 2026-10-21 | BORGESON JOHN A. · Chief Financial Officer | Open-market sale | 8,514 | $87.67 | $746K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 187 reporting institutions held 58.0M shares ($2.1B, 88.7% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BAKER BROS. ADVISORS LP | 19,919,186 | $759.3M |
| 2 | BlackRock, Inc. | 3,935,302 | $150.0M |
| 3 | STATE STREET CORP | 2,250,920 | $85.8M |
| 4 | BRAIDWELL LP | 1,818,665 | $69.3M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 1,717,076 | $65.5M |
| 6 | GOLDMAN SACHS GROUP INC | 1,689,003 | $64.4M |
| 7 | RTW INVESTMENTS, LP | 1,487,934 | $56.7M |
| 8 | TCG Crossover Management, LLC | 1,445,538 | $55.1M |
| 9 | Boxer Capital Management, LLC | 1,361,000 | $51.9M |
| 10 | JANUS HENDERSON GROUP PLC | 1,325,457 | $50.5M |
| 11 | ICONIQ Capital, LLC | 1,266,563 | $48.3M |
| 12 | Ikarian Capital, LLC | 1,265,795 | $48.3M |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 1,000,411 | $38.1M |
| 14 | SILVERARC CAPITAL MANAGEMENT, LLC | 991,930 | $37.8M |
| 15 | CITADEL ADVISORS LLC | 870,788 | $33.2M |